GE Healthcare (NYSE:GE) announced today that it has acquired Zionexa and its molecular imaging agent that could enable more targeted treatment for metastatic breast cancer patients. The financial terms of the deal were not disclosed. Zionexa (Aubière, France) has had its FDA-approved PET imaging agent Cerianna on the U.S. market since December 2020, but it’s […]